You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Simple, low cost assay for detection of HIV-1 antiretroviral resistance in resource-limited settings

    SBC: Discidium Biosciences, LLC            Topic: NIAID

    Antiretroviral therapy has become a reality in resource limited settings thanks to entities such as PEFAR and the Global Fund However contrary to the therapeutic choice flexibility in developed countries all patients go on reverse transcriptase inhibitor RTI based first line regimens with more expensive protease and integrase inhibitor based regimens being reserved as second line therapy for ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  2. Development of a Designer Proline-rich antimicrobial peptide Chaperone protein inhibitor (DPC) for treating multi-drug resistant wound infections

    SBC: Arrevus, Inc.            Topic: NIAID

    Project SummaryOver $billion is spent annually in the US treating chronicnon healing woundsmany of which face lifethreatening complications due to infectionsWound infections are difficult to treat due to the frequency of antibiotic resistance as well as the formation of biofilmsa community of bacteria covered by an extracellular polymeric substanceBiofilm related infections can result in a substan ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  3. Chemical Libraries Targeting Epigenetic Methyl Writers and Erasers

    SBC: Epicypher, Inc.            Topic: 102

    PROJECT SUMMARYIn this proposalEpiCypher is partnering with DrJian Jina leader in medicinal chemistry and epigenetic drug discoveryto develop the first epigenetics focused chemical library for histone methylationSmall molecule inhibitors that target histone methylation are an emerging class of therapeutics for cancer treatmentThis hot bed of drug development is fueled by the identification of nume ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  4. Fluorescent nanofoldamers for multiplex flow cytometry

    SBC: Nirvana Sciences, Inc.            Topic: 400

    PROJECT SUMMARY ABSTRACT Polychromatic flow cytometryFCis one of the most powerful analytical techniques used in immunologybasic researchand clinical medicineIn basic researchFC is a primary tool for understanding disease development at the cellular and subcellular levelsIn the rapidly developing field of immunotherapyFC is an indispensable tool for monitoring the effectiveness of new therapies an ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  5. Targeting glioblastoma stem-like cells with custom-designed viral vectors

    SBC: Lacerta Therapeutics, Inc.            Topic: 102

    Abstract GlioblastomaGBMis the most lethal form of adult brain cancers with a median survival of andltmonths despite aggressive standard chemoradiationGBM are formed by GBM stem like cellsGSCsa major contributor to tumor recurrence and a natural focus for therapeutic developmentThere are two main reasons responsible for treatment failurehigh intraand inter tumor cellular and molecular heterogeneit ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  6. Development of PAR2 Inhibitors for the Treatment of Nonalcoholic steatohepatitis

    SBC: OASIS PHARMACEUTICALS, LLC            Topic: NIDDK

    DESCRIPTION (provided by applicant): Non-alcoholic steatohepatitis (NASH) is characterized by fatty changes in the liver with inflammation and hepatocellular injury that in advanced stages leads to fibrosis and cirrhosis and high mortality rates. NASH is frequently associated with other common metabolic abnormalities, such as insulin resistance and visceral obesity. Liver transplantation is curren ...

    STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  7. Discovery of TrkC agonist antibodies for hearing loss

    SBC: ZEBRA BIOLOGICS INC            Topic: NIDCD

    ! Project Summary AbstractSensori neural hearing lossSNHLis caused by several factorsincluding excessive noisedrug toxin exposure and genetic lesionsTaken togetherhearing deficits represent the number one neurological disorder worldwideDespite numerous past and ongoing clinical studies there is currently no effective therapeutic treatment for hearing loss and its associated decline in quality of l ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  8. Evaluation of therapeutic efficacy and safety of novel small RNA target delivery platform in vivo.

    SBC: Oncoimmune Inc            Topic: 100

    Project Summary AbstractThe recent rapid expansion of genomic data greatly contributes to the understanding of disease development and progressionTo translate these genetic discoveries into clinical applicationswe need to develop therapeutic platforms that can specifically modulate the expression of disease related genes in vivoSmall RNAssuch as microRNAs and siRNAs function in messenger RNA silen ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  9. Development of a novel platform to enhance intracellular bioavailability of antisense morpholino oligomers

    SBC: NAJIT TECHNOLOGIES, INC.            Topic: NIAID

    DESCRIPTION provided by applicant Peptide conjugated phosphorodiamidate morpholino oligomers PPMO are single stranded nucleic acid analogs able to modulate gene expression through steric blocking of complementary RNA PPMO are composed of two components an antisense morpholino oligomer cargo covalently conjugated to a cell penetrating delivery peptide PPMO are completely nuclease resistant ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  10. Small Molecule targeting of NADPH oxidase in neutrophils

    SBC: P2D, INC            Topic: NHLBI

    DESCRIPTION (provided by applicant): Acute lung injury (ALI) and Acute Respiratory Distress Syndrome (ARDS) are characterized by a rapid and severe respiratory failure, arising after clinical events including major surgery, trauma, multiple transfusions and sepsis. ALI/ARDS have an associated mortality of 40-80% and current pharmacological modalities have been unsuccessful in decreasing mortality. ...

    STTR Phase I 2010 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government